Drug Trial Radar · NCT00703326
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
Last checked: Nov 20, 2026Latest source record: Dec 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,144
Actual
Start
Aug 6, 2008
Primary completion
Mar 31, 2013
Study completion Nov 19, 2020
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jun 23, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to compare the progression-free survival (PFS) of the drug combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated participants with human epidermal growth factor receptor 2 (HER2)-negative, unresectable, locally-recurrent or metastatic breast cancer.
Conditions
- Breast Cancer
Interventions
ramucirumab (IMC-1121B)Biological
Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
docetaxelDrug
Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
PlaceboOther
Placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Randomization to disease progression or death or until data cutoff of 31 Mar 2013 (up to 56 months)
Locations
232 sites in 23 countries. Site status is shown where the registry gives one.
ImClone Investigational Site
Birmingham, Alabama
ImClone Investigational Site
Mobile, Alabama
ImClone Investigational Site
Chandler, Arizona
ImClone Investigational Site
Gilbert, Arizona
ImClone Investigational Site
Mesa, Arizona
ImClone Investigational Site
Alhambra, California
ImClone Investigational Site
Bakersfield, California
ImClone Investigational Site
Chula Vista, California
ImClone Investigational Site
La Mesa, California
ImClone Investigational Site
Los Angeles, California
ImClone Investigational Site
Oceanside, California
ImClone Investigational Site
Pasadena, California
ImClone Investigational Site
Pasadena, California
ImClone Investigational Site
San Diego, California
ImClone Investigational Site
Santa Barbara, California
ImClone Investigational Site
Santa Maria, California
ImClone Investigational Site
Santa Monica, California
ImClone Investigational Site
Solvang, California
ImClone Investigational Site
Valencia, California
ImClone Investigational Site
Aurora, Colorado
ImClone Investigational Site
Fort Lauderdale, Florida
ImClone Investigational Site
Gainesville, Florida
ImClone Investigational Site
New Port Richey, Florida
ImClone Investigational Site
Atlanta, Georgia
ImClone Investigational Site
Atlanta, Georgia
ImClone Investigational Site
Macon, Georgia
ImClone Investigational Site
Marietta, Georgia
ImClone Investigational Site
Alton, Illinois
ImClone Investigational Site
Chicago, Illinois
ImClone Investigational Site
Chicago, Illinois
ImClone Investigational Site
Skokie, Illinois
ImClone Investigational Site
Elkhart, Indiana
ImClone Investigational Site
Mishawaka, Indiana
ImClone Investigational Site
South Bend, Indiana
ImClone Investigational Site
Westville, Indiana
ImClone Investigational Site
Lexington, Kentucky
ImClone Investigational Site
Lansing, Michigan
ImClone Investigational Site
Saint Joseph, Michigan
ImClone Investigational Site
Minneapolis, Minnesota
ImClone Investigational Site
Southaven, Mississippi
Showing 40 of 232 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.